Abstract B62: Potent single agent in vivo activity of the PARP inhibitor veliparib (ABT-888) in <i>BRCA</i>-deficient xenografts (MX-1 and Capan-1).Cherrie K. Donawho, Joann P. Palma, Lance Kaleta et al.|Molecular Cancer Therapeutics|2011Cited by 1